Skip to main content
NCBI home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 1996 Oct-Dec;2(4):289–298. doi: 10.3201/eid0204.960404

New vaccines for the prevention of pneumococcal infections.

H Käyhty 1, J Eskola 1
PMCID: PMC2639933  PMID: 8969245

Abstract

Streptococcus pneumoniae is a major cause of acute otitis media, pneumonia, bacteremia, and meningitis. Because in recent years antibiotic-resistant pneumococcal strains have been emerging throughout the world, vaccination against pneumococcal infections has become more urgent. The capsular polysaccharide vaccine that has been available is neither immunogenic nor protective in young children and other immunocompromised patients. Several pneumococcal proteins have been proposed as candidate vaccines, but no human studies associated with them have been reported. Clinical trials of first-generation pneumococcal conjugate vaccines have shown that covalent coupling of pneumococcal capsular polysaccharides to protein carriers improves the immunogenicity of the polysaccharides. The protective efficacy of the conjugate vaccines against carriage, acute otitis media, and invasive infections is being studied.

Full Text

The Full Text of this article is available as a PDF (68.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahman H., Käyhty H., Tamminen P., Vuorela A., Malinoski F., Eskola J. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis J. 1996 Feb;15(2):134–139. doi: 10.1097/00006454-199602000-00009. [DOI] [PubMed] [Google Scholar]
  2. Alexander J. E., Lock R. A., Peeters C. C., Poolman J. T., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun. 1994 Dec;62(12):5683–5688. doi: 10.1128/iai.62.12.5683-5688.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anderson E. L., Kennedy D. J., Geldmacher K. M., Donnelly J., Mendelman P. M. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J Pediatr. 1996 May;128(5 Pt 1):649–653. doi: 10.1016/s0022-3476(96)80130-2. [DOI] [PubMed] [Google Scholar]
  4. Barbour M. L., Booy R., Crook D. W., Griffiths H., Chapel H. M., Moxon E. R., Mayon-White D. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr Infect Dis J. 1993 Jun;12(6):478–484. doi: 10.1097/00006454-199306000-00005. [DOI] [PubMed] [Google Scholar]
  5. Bennett N. M., Buffington J., LaForce F. M. Pneumococcal bacteremia in Monroe County, New York. Am J Public Health. 1992 Nov;82(11):1513–1516. doi: 10.2105/ajph.82.11.1513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Booy R., Hodgson S., Carpenter L., Mayon-White R. T., Slack M. P., Macfarlane J. A., Haworth E. A., Kiddle M., Shribman S., Roberts J. S. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet. 1994 Aug 6;344(8919):362–366. doi: 10.1016/s0140-6736(94)91400-1. [DOI] [PubMed] [Google Scholar]
  7. Butler J. C., Breiman R. F., Campbell J. F., Lipman H. B., Broome C. V., Facklam R. R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA. 1993 Oct 20;270(15):1826–1831. [PubMed] [Google Scholar]
  8. Dagan R., Engelhard D., Piccard E., Englehard D [corrected to Engelhard D. ]. Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. JAMA. 1992 Dec 16;268(23):3328–3332. [PubMed] [Google Scholar]
  9. Englund J. A., Glezen W. P., Turner C., Harvey J., Thompson C., Siber G. R. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis. 1995 Jan;171(1):99–105. doi: 10.1093/infdis/171.1.99. [DOI] [PubMed] [Google Scholar]
  10. Eskola J., Käyhty H., Takala A. K., Peltola H., Rönnberg P. R., Kela E., Pekkanen E., McVerry P. H., Mäkelä P. H. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med. 1990 Nov 15;323(20):1381–1387. doi: 10.1056/NEJM199011153232004. [DOI] [PubMed] [Google Scholar]
  11. Eskola J., Takala A. K., Kela E., Pekkanen E., Kalliokoski R., Leinonen M. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA. 1992 Dec 16;268(23):3323–3327. [PubMed] [Google Scholar]
  12. Fattom A., Vann W. F., Szu S. C., Sutton A., Li X., Bryla D., Schiffman G., Robbins J. B., Schneerson R. Synthesis and physicochemical and immunological characterization of pneumococcus type 12F polysaccharide-diphtheria toxoid conjugates. Infect Immun. 1988 Sep;56(9):2292–2298. doi: 10.1128/iai.56.9.2292-2298.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Giebink G. S., Koskela M., Vella P. P., Harris M., Le C. T. Pneumococcal capsular polysaccharide-meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis. 1993 Feb;167(2):347–355. doi: 10.1093/infdis/167.2.347. [DOI] [PubMed] [Google Scholar]
  14. Giebink G. S., Meier J. D., Quartey M. K., Liebeler C. L., Le C. T. Immunogenicity and efficacy of Streptococcus pneumoniae polysaccharide-protein conjugate vaccines against homologous and heterologous serotypes in the chinchilla otitis media model. J Infect Dis. 1996 Jan;173(1):119–127. doi: 10.1093/infdis/173.1.119. [DOI] [PubMed] [Google Scholar]
  15. Goebel W. F., Avery O. T. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : I. THE SYNTHESIS OFp-AMINOPHENOL beta-GLUCOSIDE, p-AMINOPHENOL beta-GALACTOSIDE, AND THEIR COUPLING WITH SERUM GLOBULIN. J Exp Med. 1929 Sep 30;50(4):521–531. doi: 10.1084/jem.50.4.521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kauppi M., Eskola J., Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J. 1995 Apr;14(4):286–294. doi: 10.1097/00006454-199504000-00008. [DOI] [PubMed] [Google Scholar]
  17. Kauppi M., Saarinen L., Käyhty H. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J Infect Dis. 1993 Feb;167(2):365–371. doi: 10.1093/infdis/167.2.365. [DOI] [PubMed] [Google Scholar]
  18. Klugman K. P. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990 Apr;3(2):171–196. doi: 10.1128/cmr.3.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Käyhty H., Ahman H., Rönnberg P. R., Tillikainen R., Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis. 1995 Nov;172(5):1273–1278. doi: 10.1093/infdis/172.5.1273. [DOI] [PubMed] [Google Scholar]
  20. Käyhty H., Eskola J., Peltola H., Stout M. G., Samuelson J. S., Gordon L. K. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J Infect Dis. 1987 Jan;155(1):100–106. doi: 10.1093/infdis/155.1.100. [DOI] [PubMed] [Google Scholar]
  21. Leach A., Ceesay S. J., Banya W. A., Greenwood B. M. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr Infect Dis J. 1996 Apr;15(4):333–339. doi: 10.1097/00006454-199604000-00010. [DOI] [PubMed] [Google Scholar]
  22. Lee C. J., Lock R. A., Andrew P. W., Mitchell T. J., Hansman D., Paton J. C. Protection of infant mice from challenge with Streptococcus pneumoniae type 19F by immunization with a type 19F polysaccharide--pneumolysoid conjugate. Vaccine. 1994 Aug;12(10):875–878. doi: 10.1016/0264-410x(94)90028-0. [DOI] [PubMed] [Google Scholar]
  23. Lock R. A., Paton J. C., Hansman D. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae. Microb Pathog. 1988 Dec;5(6):461–467. doi: 10.1016/0882-4010(88)90007-1. [DOI] [PubMed] [Google Scholar]
  24. Luotonen J., Herva E., Karma P., Timonen M., Leinonen M., Mäkelä P. H. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis. 1981;13(3):177–183. doi: 10.3109/inf.1981.13.issue-3.04. [DOI] [PubMed] [Google Scholar]
  25. McDaniel L. S., Sheffield J. S., Delucchi P., Briles D. E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun. 1991 Jan;59(1):222–228. doi: 10.1128/iai.59.1.222-228.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Mulholland K., Suara R. O., Siber G., Roberton D., Jaffar S., N'Jie J., Baden L., Thompson C., Anwaruddin R., Dinan L. Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in The Gambia. JAMA. 1996 Apr 17;275(15):1182–1188. [PubMed] [Google Scholar]
  27. Mäkelä O., Mattila P., Rautonen N., Seppälä I., Eskola J., Käyhty H. Isotype concentrations of human antibodies to Haemophilus influenzae type b polysaccharide (Hib) in young adults immunized with the polysaccharide as such or conjugated to a protein (diphtheria toxoid). J Immunol. 1987 Sep 15;139(6):1999–2004. [PubMed] [Google Scholar]
  28. Mäkelä P. H., Sibakov M., Herva E., Henrichsen J., Luotonen J., Timonen M., Leinonen M., Koskela M., Pukander J., Pöntynen S. Pneumococcal vaccine and otitis media. Lancet. 1980 Sep 13;2(8194):547–551. doi: 10.1016/s0140-6736(80)91989-3. [DOI] [PubMed] [Google Scholar]
  29. Paton J. C., Lock R. A., Hansman D. J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun. 1983 May;40(2):548–552. doi: 10.1128/iai.40.2.548-552.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Powers D. C., Anderson E. L., Lottenbach K., Mink C. M. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis. 1996 Apr;173(4):1014–1018. doi: 10.1093/infdis/173.4.1014. [DOI] [PubMed] [Google Scholar]
  31. Quataert S. A., Kirch C. S., Wiedl L. J., Phipps D. C., Strohmeyer S., Cimino C. O., Skuse J., Madore D. V. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995 Sep;2(5):590–597. doi: 10.1128/cdli.2.5.590-597.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Riley I. D., Lehmann D., Alpers M. P., Marshall T. F., Gratten H., Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet. 1986 Oct 18;2(8512):877–881. doi: 10.1016/s0140-6736(86)90409-5. [DOI] [PubMed] [Google Scholar]
  33. Sampson J. S., O'Connor S. P., Stinson A. R., Tharpe J. A., Russell H. Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins. Infect Immun. 1994 Jan;62(1):319–324. doi: 10.1128/iai.62.1.319-324.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sankilampi U., Honkanen P. O., Bloigu A., Herva E., Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis. 1996 Feb;173(2):387–393. doi: 10.1093/infdis/173.2.387. [DOI] [PubMed] [Google Scholar]
  35. Sarvas H., Rautonen N., Sipinen S., Mäkelä O. IgG subclasses of pneumococcal antibodies--effect of allotype G2m(n). Scand J Immunol. 1989 Feb;29(2):229–237. doi: 10.1111/j.1365-3083.1989.tb01120.x. [DOI] [PubMed] [Google Scholar]
  36. Schneerson R., Levi L., Robbins J. B., Bryla D. M., Schiffman G., Lagergard T. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin. Infect Immun. 1992 Sep;60(9):3528–3532. doi: 10.1128/iai.60.9.3528-3532.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Schneerson R., Robbins J. B., Parke J. C., Jr, Bell C., Schlesselman J. J., Sutton A., Wang Z., Schiffman G., Karpas A., Shiloach J. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun. 1986 May;52(2):519–528. doi: 10.1128/iai.52.2.519-528.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Shahid N. S., Steinhoff M. C., Hoque S. S., Begum T., Thompson C., Siber G. R. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet. 1995 Nov 11;346(8985):1252–1257. doi: 10.1016/s0140-6736(95)91861-2. [DOI] [PubMed] [Google Scholar]
  39. Shapiro E. D., Berg A. T., Austrian R., Schroeder D., Parcells V., Margolis A., Adair R. K., Clemens J. D. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991 Nov 21;325(21):1453–1460. doi: 10.1056/NEJM199111213252101. [DOI] [PubMed] [Google Scholar]
  40. Shurin P. A., Rehmus J. M., Johnson C. E., Marchant C. D., Carlin S. A., Super D. M., Van Hare G. F., Jones P. K., Ambrosino D. M., Siber G. R. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr. 1993 Nov;123(5):801–810. doi: 10.1016/s0022-3476(05)80865-0. [DOI] [PubMed] [Google Scholar]
  41. Sniadack D. H., Schwartz B., Lipman H., Bogaerts J., Butler J. C., Dagan R., Echaniz-Aviles G., Lloyd-Evans N., Fenoll A., Girgis N. I. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children--implications for vaccine strategies. Pediatr Infect Dis J. 1995 Jun;14(6):503–510. [PubMed] [Google Scholar]
  42. Stansfield S. K. Acute respiratory infections in the developing world: strategies for prevention, treatment and control. Pediatr Infect Dis J. 1987 Jul;6(7):622–629. doi: 10.1097/00006454-198707000-00002. [DOI] [PubMed] [Google Scholar]
  43. Steinhoff M. C., Edwards K., Keyserling H., Thoms M. L., Johnson C., Madore D., Hogerman D. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J. 1994 May;13(5):368–372. doi: 10.1097/00006454-199405000-00007. [DOI] [PubMed] [Google Scholar]
  44. Tart R. C., McDaniel L. S., Ralph B. A., Briles D. E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis. 1996 Feb;173(2):380–386. doi: 10.1093/infdis/173.2.380. [DOI] [PubMed] [Google Scholar]
  45. Vella P. P., Marburg S., Staub J. M., Kniskern P. J., Miller W., Hagopian A., Ip C., Tolman R. L., Rusk C. M., Chupak L. S. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide types 6B, 14, 19F, and 23F and a meningococcal outer membrane protein complex. Infect Immun. 1992 Dec;60(12):4977–4983. doi: 10.1128/iai.60.12.4977-4983.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. de Velasco E. A., Merkus D., Anderton S., Verheul A. F., Lizzio E. F., Van der Zee R., Van Eden W., Hoffman T., Verhoef J., Snippe H. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines. Infect Immun. 1995 Mar;63(3):961–968. doi: 10.1128/iai.63.3.961-968.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. van de Wijgert J. H., Verheul A. F., Snippe H., Check I. J., Hunter R. L. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution. Infect Immun. 1991 Aug;59(8):2750–2757. doi: 10.1128/iai.59.8.2750-2757.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES